The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Panitumumab and cetuximab target the epidermal growth factor receptor for the treatment of metastatic colorectal cancer. These therapies provide a significant survival benefit to patients with metastatic colorectal cancer with wild-type RAS. A single point mutation in the ectodomain of EGFR (S468R) confers acquired or secondary resistance in cetuximab treated patients, which is not observed in panitumumab-treated patients. Structural and biophysical studies presented here show this mutation directly blocks cetuximab binding to EGFR domain III and describes a unique mechanism by which panitumumab uses a central cavity to accommodate this mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig 4 EGFR domain III mutants. (A) Panitumumab epitope on EGFR domain III of EGFR is shown in yellow. EGF binding surface on EGFR domain III is shown in red (PDB:1IVO). Mutations are shown on surface relative to panitumumab epitope and EGF binding interface. EGF and panitumumab have significant overlap in the domain III binding surfaces. S468R as well as many additional mutations are located on the perimeter of the EGF binding site but are centrally located in the panitumumab epitope. (B-E) Panitumumab is shown in magenta and cetuximab is shown in cyan. Red lettering represents mutation and the number in parenthesis represents numbering based on mature protein sequence used in the crystal structure. The remaining residues are numbered to be consistent with crystal structure numbering. (B)The K467T mutation will result in a clash with W94 in cetuximab but rotamer conformations exist that would minimize the steric clash in panitumumab, as a result cetuximab is sensitive to this mutation but panitumumab remains active. [13]. (C) I491M would result in steric clashes with D103 and Y102 in cetuximab and F91 and the main chain of T103 in panitumumab. (D) G465R would result in steric clashes with W52 and His35 in cetuximab and H52 and Y35 in panitumumab. (E) S464L is in a tightly packed region and would clash with Y102 and Y104 in cetuximab and V102 and Y35 in panitumumab.](https://figures.cochat.ai/paper-figures/3bc4c5e6fbd6476493d011c539111022/the-panitumumab-egfr-complex-reveals-a-binding-mechanism-that-overcomes-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Fortunately, the S492R mutation does not confer resistance to panitumumab [33,35,36,37].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Research works printed but not linked: 1
- Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P et al Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014; 15: 569– 79. 10.1016/S1470-2045(14)70118-4 24739896 · DOI · Paper page
Cited by
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
Immunoliposomes: A review on functionalization strategies and targets for drug delivery
Eloy, J. O., Petrilli, R., Trevizan, L. N. F., & Chorilli, M. (2017) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2017.07.085 · Cited by 209
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
García-Foncillas, J., Sunakawa, Y., Aderka, D., Wainberg, Z., Ronga, P., Witzler, P., & Stintzing, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00849 · Cited by 201
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
Amelia, T., Kartasasmita, R. E., Ohwada, T., & Tjahjono, D. H. (2022) · Molecules · doi:10.3390/molecules27030819 · Cited by 158
Kaufman, N. E. M., Dhingra, S., Jois, S. D. S., & Vicente, M. G. H. (2021) · Molecules · doi:10.3390/molecules26041076 · Cited by 143
Monoclonal antibody-based molecular imaging strategies and theranostic opportunities
Dammes, N., & Peer, D. (2020) · Theranostics · doi:10.7150/thno.37443 · Cited by 138
Montagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5245 · Cited by 135
“9) 27 (16-41) 1 [Reference] Abbreviations: ITT, intent-to-treat; HR, hazard ratio; OS, overall survival.”
Gramespacher, J. A., Cotton, A. D., Burroughs, P., Seiple, I. B., & Wells, J. A. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00185 · Cited by 108
Helden, E. J. V., Angus, L., van Oordt, C. W. M. D. H., Heideman, D. A. M., Boon, E., van Es, S. C., Radema, S. A., van Herpen, C. M. L., de Groot, D. J. A., de Vries, E. G. E., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12550 · Cited by 85
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
Angelbello, A. J., Chen, J. L., Childs‐Disney, J. L., Zhang, P., Wang, Z.-F., & Disney, M. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00504 · Cited by 81
Zhang, Y. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000906 · Cited by 74
Mizukami, T., Izawa, N., Nakajima, T. E., & Sunakawa, Y. (2019) · Drugs · doi:10.1007/s40265-019-01113-0 · Cited by 65
Bagchi, A., Haidar, J. N., Eastman, S. W., Vieth, M., Topper, M., Iacolina, M. D., Walker, J. M., Forest, A., Shen, Y., Novosiadly, R. D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0575 · Cited by 60
Banach, B. B., Cerutti, G., Fahad, A. S., Shen, C.-H., Oliveira De Souza, M., Katsamba, P. S., Tsybovsky, Y., Wang, P., Nair, M. S., Huang, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109771 · Cited by 60
Makowski, E. K., Wang, T., Zupancic, J. M., Huang, J., Wu, L., Schardt, J. S., Groot, A. S. D., Elkins, S. L., Martin, W. D., & Tessier, P. M. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01074-6 · Cited by 59
Liu, Z., He, K., Ma, Q., Yu, Q., Liu, C., Ndege, I., Wang, X., & Yu, Z. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177694 · Cited by 55
Glycans as Targets for Drug Delivery in Cancer
Diniz, F., Coelho, P., Duarte, H. O., Sarmento, B. F. C. C., Reis, C. A., & Gomes, J. (2022) · Cancers · doi:10.3390/cancers14040911 · Cited by 55
Burande, A. S., Viswanadh, M. K., Jha, A., Mehata, A. K., Shaik, A., Agrawal, N., Poddar, S., Mahto, S. K., & Muthu, M. S. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01671-7 · Cited by 54
RetractedNovel redox-sensitive thiolated TPGS based nanoparticles for EGFR targeted lung cancer therapy
Viswanadh, M. K., Agrawal, N., Shaik, A., Jha, A., Poddar, S., Mahto, S. K., & Muthu, M. S. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120652 · Cited by 48
Gastric cancer management: Kinases as a target therapy
Farran, B., Müller, S., & Montenegro, R. C. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12743 · Cited by 44
Immune Effector Functions of Human IgG2 Antibodies against EGFR
Rösner, T., Kahle, S., Montenegro, F., Matlung, H. L., Jansen, J. H. M., Evers, M., Beurskens, F. J. M., Leusen, J. H. W., van den Berg, T. K., & Valerius, T. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0341 · Cited by 42
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017) · Cancers · doi:10.3390/cancers9040033 · Cited by 41
Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers
Hwang, K., Yoon, J. H., Lee, J., & Lee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9010039 · Cited by 43
Fu, W., Lei, C., Yu, Y., Liu, S., Li, T., Lin, F., Fan, X., Shen, Y., Ding, M., Tang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2732 · Cited by 40
Therapeutic antibodies for the prevention and treatment of cancer
Kumar, M., Jalota, A., Sahu, S. K., & Haque, S. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00996-w · Cited by 39
Recombinant Antibody Engineering Enables Reversible Binding for Continuous Protein Biosensing
Fercher, C., Jones, M. L., Mahler, S. M., & Corrie, S. R. (2021) · ACS Sensors · doi:10.1021/acssensors.0c01510 · Cited by 34
Safety switch optimization enhances antibody-mediated elimination of CAR T cells
Shabaneh, T. B., Moffett, H. F., Stull, S. M., Derezes, T., Tait, L. J., Park, S., Riddell, S., & Lajoie, M. J. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1026474 · Cited by 32
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
Bignucolo, A., Mattia, E. D., Cecchin, E., Roncato, R., & Toffoli, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071522 · Cited by 29
Zhuang, X., Wang, Z., Fan, J., Bai, X., Xu, Y., Chou, J. J., Hou, T., Chen, S., & Pan, L. (2022) · Nature Communications · doi:10.1038/s41467-022-32159-6 · Cited by 27
Epitope Mapping of an Antihuman EGFR Monoclonal Antibody (EMab-134) Using the REMAP Method
Sano, M., Kaneko, M. K., Asano, T., & Kato, Y. (2021) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2021.0014 · Cited by 27
Pyrene-Modified DNA Aptamers with High Affinity to Wild-Type EGFR and EGFRvIII
Zavyalova, E. G., Turashev, A. D., Novoseltseva, A. A., Legatova, V. A., Antipova, O. M., Savchenko, E., Balk, S., Golovin, A. V., Pavlova, G. V., & Kopylov, A. M. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0830 · Cited by 26
Kaserer, T., & Blagg, J. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.07.013 · Cited by 24
Gavriil, E.-S., Doukatas, A., Karampelas, T., Myrianthopoulos, V., Dimitrakis, S., Mikros, E., Marakos, P., Tamvakopoulos, C., & Pouli, N. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.029 · Cited by 25
Martin, J., Lehmann, A., Klauschen, F., Hummel, M., Lenze, D., Grohé, C., Tessmer, A., Gottschalk, J., Schmidt, B., Pau, H. W., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.04.012 · Cited by 23
Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
Makabe, K., Yokoyama, T., Uehara, S., Uchikubo‐Kamo, T., Shirouzu, M., Kimura, K., Tsumoto, K., Asano, R., Tanaka, Y., & Kumagai, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-84171-3 · Cited by 18
Krieg, D., Winter, G., & Svilenov, H. L. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.05.014 · Cited by 17
Sreedurgalakshmi, K., Srikar, R., Harikrishnan, K., Srinivasan, L., & Rajkumari, R. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211041453 · Cited by 16
Islam, J., Riley, B. T., Fercher, C., Jones, M. L., Buckle, A. M., Howard, C. B., Cox, R. P., Bell, T. D. M., Mahler, S. M., & Corrie, S. R. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b00445 · Cited by 14
Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics
Tydings, C. W., Singh, B., Smith, A. W., Ledwitch, K. V., Brown, B. P., Lovly, C. M., Walker, A. S., & Meiler, J. (2024) · Protein Science · doi:10.1002/pro.5141 · Cited by 13
Barlow, K. A., Battles, M. B., Brown, M. E., Canfield, K., Lu, X., Lynaugh, H., Morrill, M. B., Rappazzo, C. G., Reyes, S. P., Sandberg, C., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2479531 · Cited by 13
Chandramouli, M., Pasha, T. Y., Rahamathulla, M., Gagana, H. P., Kavya, B., Gagana, K. M., Purushotham, K. N., Hussain, S. M., Ahmed, M. M., Shivanandappa, T. B., et al. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2024.2449495 · Cited by 12
Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR
Wagner, A., Galicia‐Andrés, E., Teufl, M., Gold, L., Obinger, C., Sykacek, P., Oostenbrink, C., & Traxlmayr, M. W. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00384 · Cited by 10
Hosseini, S. M., Mohammadnejad, J., Yousefnia, H., Alirezapour, B., & Rezayan, A. H. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04724-z · Cited by 10
Mitropoulou, A. N., Ceska, T., Heads, J. T., Beavil, A. J., Henry, A. J., McDonnell, J. M., Sutton, B. J., & Davies, A. M. (2020) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x20001466 · Cited by 9
Covalent N-arylation by the pollutant 1,2-naphthoquinone activates the EGF receptor
Nakahara, K., Hamada, K., Tsuchida, T., Takasugi, N., Abiko, Y., Shien, K., Toyooka, S., Kumagai, Y., & Uehara, T. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100524 · Cited by 9
Krebs, S. K., Rakotoarinoro, N., Stech, M., Zemella, A., & Kubick, S. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.873906 · Cited by 9
Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review
Wijetunga, I., McVeigh, L. E., Charalambous, A., Antanaviciute, A., Carr, I., Nair, A., Prasad, R. K., Ingram, N., & Coletta, P. L. (2020) · Cancers · doi:10.3390/cancers12102817 · Cited by 7
Accurate antibody loop structure prediction enables zero-shot design of target-specific antibodiesPreprint
Bang, Y., Choi, Y., Gu, J., Kwon, S., Lee, D., Lee, E. S., Lee, M. S., Lee, S., Lee, S., Lee, M. S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.23.609114 · Cited by 6
Xu, L., Li, L., Zhang, J., Cai, W., Zhao, S., & Liu, S. (2019) · Odontology · doi:10.1007/s10266-019-00451-5 · Cited by 5
Mahvi, D. A., & Mahvi, D. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00058-x · Cited by 5
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
“Importantly, panitumumab binds to a different epitope on EGFR and retains activity against tumors harboring the S492R mutation, which explains why patients with this mutation may still respond to panitumumab but not cetuximab [116,119].”
Allosteric Antibody Modulation of EGFR Activity: Bridging Experiment and In Silico Modeling
Fournier, L., Becker, S., Zielonka, S., & Guarnera, E. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169315 · Cited by 4
A disruptive clickable antibody design for the generation of antibody-drug conjugates
Rakotoarinoro, N., Dyck, Y. F. K., Krebs, S. K., Assi, M.-K., Parr, M. K., & Stech, M. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad023 · Cited by 4
Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0
Chan, C., Jansen, J. H. M., Hendriks, I. S. T., van der Peet, I. C., Verdonschot, M. E. L., Passchier, E. M., Tsioumpekou, M., Nederend, M., Klomp, S. A., Valerius, T., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0217 · Cited by 4
Jacobitz, A. W., Rodezno, W., & Agrawal, N. J. (2022) · AAPS Open · doi:10.1186/s41120-022-00057-2 · Cited by 4
An Overview of Target Membrane Proteins for Near-Infrared Photoimmunotherapy
Suzuki, M., & Hanaoka, H. (2025) · Pharmaceuticals · doi:10.3390/ph18091419 · Cited by 3
Hamabe, M., Dewa, W., Yuki, M., Yamada, E., Aiba, T., Horikoshi, K., Hamakubo, T., Ohashi, R., & Okamoto, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00931b · Cited by 3
Chun, C., Sohn, B.-K., Ki, H., Jo, J. H., An, H.-T., Park, J., Lee, J., Choi, S., Choi, J. H., Cho, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.21.719857 · Cited by 3
Novel bispecific T-cell engagers overcoming acquired EGFR resistance
Kühl, L., Löffler, A.-K., Seifert, O., Michler, D., Kuhlmann, M., Russo, G., Kuhn, P., Nowack, H., Frenzel, A., Schirrmann, T., et al. (2026) · mAbs · doi:10.1080/19420862.2026.2674236 · Cited by 2
Adams, J., Mallette, E., London, M., Liang, R. J., van Dyk, D., Pavlovic, Z., Pot, I., Geyer, C. R., Bruce, H. A., Blazer, L. L., et al. (2026) · Protein Science · doi:10.1002/pro.70645 · Cited by 2
Zacharias, N. M., Rupe, E. S., Chen, X., Kotecha, R. R., Rieke, D. T., McGregor, B. A., Pesquera, P. I., Yu, Z., Grover, A., Daw, N. C., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0392 · Cited by 2
Molecular mechanism of EGFR signaling evoked by environmental pollutant 1,2-naphthoquinone
Tsuchida, T., & Uehara, T. (2022) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22043 · Cited by 2
Adriani, R. R., Gargari, S. L. M., Bakherad, H., & Amani, J. (2024) · Quantitative Biology · doi:10.1002/qub2.63 · Cited by 2
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“Fortunately, the S492R mutation does not confer resistance to panitumumab [33,35–37].”
Lebedeva, A. A., Kavun, A., Belova, E. V., Antonova, T. G., & Semenova, A. B. (2025) · RESEARCH RESULTS IN BIOMEDICINE · doi:10.18413/2658-6533-2025-11-1-0-1 · Cited by 1
Selectivity Approaches in Therapeutic Antibody Design
Fouad, M. A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01830 · Cited by 1
Harmych, S. J., Joshi, N., Tanaka, H., Bogatcheva, G. T., Ramirez, M. A., Graves‐Deal, R., Tydings, C. W., Elia, M. T., Mueller, H. R. L., Silvestri, I. M., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218607 · Cited by 1
Nojima, H., Kiyota, Y., Terashi, G., Takeda‐Shitaka, M., & Matsubara, H. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00205 · Cited by 1
М'ясоєдов, В. В. (. В. Р. )., Єрмоленко, Т. І., & Шаповал, О. М. (2023) · Kharkiv National Medical University Repository (Kharkiv National Medical University) · Cited by 1
A reproducible molecular dynamics benchmark for ADC epitope triage in EGFR and HER2Preprint
shakeel, H. (2026) · ChemRxiv · doi:10.21203/rs.3.rs-8820222/v1 · Cited by 1
Maza, J. C., Peters-Clarke, T. M., Chen, Y., Raguveer, S., Burroughs, P., Le, S., Seto, M., Leung, K., & Wells, J. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.18.733223 · Cited by 1
Development of one-step fluorescent biosensors by exploiting engineered antibodies
Islam, J. (2020) · Figshare · doi:10.26180/11589843
Zeronian, M. R. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/821
Bagchi, A., Haidar, J. N. S., Eastman, S. W., Vieth, M., Topper, M. J., Iacolina, M. D., Walker, J. M., Forest, A., Shen, Y., Novosiadly, R. D., et al. (2023) · doi:10.1158/1535-7163.22510134
Novel targeting strategies on signaling pathways of colorectal cancer
Sabale, P., Waghmare, S., Potey, L., Khedekar, P. B., Sabale, V., Rarokar, N. R., Chikhale, R. V., & Palekar, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00017-9
Multi-Objective Engineering of Therapeutic Antibodies
Makowski, E. K. (2023) · Deep Blue (University of Michigan) · doi:10.7302/7296
Design and generation of antibody-drug conjugates using non-canonical amino acids
Rakotoarinoro, N. (2023) · Refubium (Universitätsbibliothek der Freien Universität Berlin) · doi:10.17169/refubium-41950
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Figshare · doi:10.6084/m9.figshare.21301428
Baumann, N. (2023) · MACAU: Open Access Repository of Kiel University (University Library Kiel)
Phage Display for the Development of Synthetic Antibodies Targeting Receptor Tyrosine Kinases
London, M. E. (2018) · TSpace (University of Toronto)
Das, S. K., Dutta, S., Pradhan, S., & Saikia, R. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04314-8
Sauer, N. J., Giedziun, P., Calik, J., & Wiela−Hojeńska, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1791359
A tethered yeast surface display system facilitates enriching epitope-specific binding interactions
Panton, R. A., Lind, J., Richardson, A., Panozzo, I., García, D. G., Muzaffar, S., & Stern, L. A. (2026) · Protein Engineering Design and Selection · doi:10.1093/protein/gzag019
Jiang, L., Han, X., He, H., Peng, M., Yang, M., Pan, J., Liu, D., Feng, H., Yan, J., & Li, L. (2026) · hLife · doi:10.1016/j.hlife.2026.08.003
Mapeo epitópico fino y evolución dirigida del anticuerpo terapéutico nimotuzumab
Tundidor, Y., Rojas, G., Pupo, A., & Hernández, C. P. G. (2023) · Anales de la Academia de Ciencias de Cuba
James, S., Kasten, B. B., Shi, J., Knight, N. D., Wodeyar, A., Eli, A. V., Kane, A. C., Morlandt, A. B., Zaidi, S. M. A., Brown, B. T., et al. (2026) · Molecular Imaging and Biology · doi:10.1007/s11307-026-02149-x
Metadata
- Authors
- Sickmier, E. A., Kurzeja, R. J. M., Michelsen, K., Vazir, M., Yang, E., & Tasker, A. S.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Sickmier, E. Allen
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-09-22
- Volume
- 11
- Issue
- 9
- Pages
- e0163366
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5033319
- OpenAlex
- W2521226389
- Cited by
- 76
- References
- 30
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 6 · 2022: 13 · 2021: 9 · 2020: 7 · 2019: 10 · 2018: 4 · 2017: 6
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, cetuximab, EGFR, epidermal growth factor receptor, cetuximab resistance, metastatic colorectal cancer, drug binding mechanism, RAS wild-type, antibody-antigen complex structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.